Apollon Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Apollon Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.5K	Buy	+10,775	New	+$35.9K	﹤0.01%	1555

Other funds holding RXRX

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return

Themes Management Co Greenwich, Connecticut $151M AUM

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Apollon Wealth Management's RXRX Position: Q2 2026 in Review

Apollon Wealth Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 10,775 shares worth $39.5K. The stake represents ﹤0.01% of the portfolio and ranks #1555 among its holdings.

58 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Apollon Wealth Management held 10,775 shares of Recursion Pharmaceuticals worth $39.5K as of Q2 2026.
Recursion Pharmaceuticals was a new Apollon Wealth Management position in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #1555 holding.
58 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.